Avalo Therapeutics, Inc. (AVTX)

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: TD Cowen Annual Healthcare Conference Fireside Chat March 3, 2026, at 9:50 am ET Leerink Partners Global Healthcare Conference Fireside ChatMarch 10, 2026, at 4:20 pm ET Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

WAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to two new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 82,000 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation

WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026 Fireside ChatFebruary 11, 2026, at 10:00 am ET Oppenheimer 36th Annual Healthcare Life Sciences Conference Fireside ChatFebruary 25, 2026, at 10:00 am ET Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

Avalo Therapeutics Inc.'s (NASDAQ: AVTX) completed enrollment of the Phase 2 LOTUS trial of AVTX-009, the company's lead drug candidate.

Avalo Therapeutics completed Phase 2 enrollment for AVTX-009, with mid-2026 data ahead. Cantor sees major upside if results impress, but warns shares could plunge if the trial disappoints.

Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating

Aditxt (NASDAQ: ADTX - Get Free Report) and Avalo Therapeutics (NASDAQ: AVTX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Profitability This table compares Aditxt and Avalo Therapeutics'

WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 114,000 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026 Appointed Kevin Lind to Board of Directors Expanded leadership team with key appointments in business development and human resources Cash and short-term investments of approximately $112 million as of September 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and financial results for the third quarter of 2025.

WAYNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Second Annual Healthcare Innovation Conference Fireside ChatNovember 10, 2025, at 4:00 pm ET Stifel 2025 Healthcare Conference Fireside ChatNovember 12, 2025, at 2:40 pm ET TD Cowen 1 st Immunology & Inflammation Summit Fireside ChatNovember 13, 2025, at 9:00 am ET Piper Sandler 37 th Annual Healthcare Conference Fireside ChatDecember 2, 2025, at 10:30 am ET Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company has completed enrollment in its Phase 2 LOTUS trial of AVTX-009 in adults with hidradenitis suppurativa (HS). The LOTUS trial exceeded target enrollment of 222 patients with approximately 250 patients enrolled. Topline data from the trial is expected in mid-2026.

WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. “We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year,” said Dr. Garry Neil, Chief Executive Officer.

WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit.

WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

Avalo Therapeutics' value mostly hinges on AVTX-009. This is an IL-1β mAb in a Phase 2 LOTUS trial for hidradenitis suppurativa. This Phase 2 trial should give us topline results by mid-2026, which I consider its most significant near-term value driver at this point. AVTX-009 also seems to have higher affinity and half-life versus Lutikizumab, which could allow for fewer doses and stronger efficacy.